Epicardial Fat, Visceral Fat and Coronary Atherosclerosis

Atherosclerosis Clinical Trial

Official title:

Association Between Epicardial Fat, Visceral Fat Accumulation & Cardiovascular Atherosclerosis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01344694
• Other study ID #: 0020-11
• Status: Not yet recruiting
• Phase: N/A
• First received: April 27, 2011
• Last updated: May 13, 2011
• Start date: July 2011
• Est. completion date: March 2012

Study information

• Verified date: April 2011
• Source: Ziv Hospital
• Contact: Nimer Assy, MD
• Phone: 972-46828442
• Email: assy.n[@]ziv.health.gov.il
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Observational

Clinical Trial Summary

Background: Visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease. The independent role of epicardial fat deposition in cardiovascular risk remains unclear.

Description:

Background: Visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease. The independent role of epicardial fat deposition in cardiovascular risk remains unclear. Aim: Evaluate the link between epicardial fat, visceral fat, liver fat accumulation and cardiovascular diseases and carotis atherosclerosis in patients with the major cardiovascular risk factors and with or without metabolic syndrome.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 110
• Est. completion date: March 2012
• Est. primary completion date: February 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 40 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients referred to cardiac CT will be the source of recruitment.

• patients with excess of visceral fat,

• 30 patients with liver fat accumulation

• 30 sex-age-matched individual (controls) will be enrolled. All patients will undergo a complete family history, personal clinical history, physical examination and blood sampling for biochemical analysis.

• Informed consent will be obtained from each individual.

Exclusion Criteria:

• subjects with severe morbid obesity (body mass index [BMI] > 40),

• recent history of acute illness,

• clinical history of ischemic heart disease and cerebrovascular disease,

• typical chest pain,

• previous coronary artery disease,

• conventional coronary angiography, percutaneous interventions, coronary by pass grafting, renal failure, cancer patients,

• subjects who take drugs that induces hepatic steatosis ( corticosteroids, estrogens, methotrexate, amiodarone and others)

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

• Atherosclerosis
• Epicardial Fat
• Visceral Fat

Intervention

Other:
• patient with liver fat
30 patient with liver fat
• pts. with excess of visceral fat
pts. with excess of visceral fat
• control
30 control subjects

Locations

Country	Name	City	State
Israel	Ziv MC	Safed

Sponsors (1)

Lead Sponsor	Collaborator
Ziv Hospital

Country where clinical trial is conducted

Israel,